证券代码：300143 证券简称：盈康生命 公告编号：2025-023 盈康生命科技股份有限公司 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》 《公司章程》及有关法律、法规的规定。 二、监事会会议审议情况 （一）审议通过《关于公司2025年第一季度报告的议案》 第六届监事会第十五次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于2025年4月25日以电话、 邮件方式向全体监事发出召开公司第六届监事会第十五次（临时）会议的通知。 本次会议于2025年4月28日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会 议室以现场的方式召开。会议应出席监事3人，实际出席监事3人，监事龚雯雯、 王旭东、李超峰以现场方式出席会议并投票表决。本次会议由监事会主席龚雯雯 女士主持，公司部分高级管理人员列席了会议。 公司监事会根据《中华人民共和国公司法》和《公司章程》的有关规定，本 着对全体股东负责的态度，谨慎履行法律、法规赋予的职责，审核了公司《2025 年第一季度报告》 ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-022 盈康生命科技股份有限公司 第六届董事会第十七次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第十七次（临时）会议的通知。会 议于 2025 年 4 月 28 日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会议室 以现场结合通讯的方式召开。会议应出席董事 7 人，实际出席董事 7 人，董事谭丽 霞、彭文以现场方式出席会议并投票表决，董事潘绵顺、沈旭东、独立董事杜媛、独 立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本次会议由董事长谭 丽霞女士主持，公司的监事、高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公司 章程》及有关法律、法规的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第一季度报告的议案》 董事会审议了公司《2025 年第一 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥409,036,863.19, a decrease of 1.73% compared to ¥416,230,884.39 in the same period last year[4] - Net profit attributable to shareholders increased by 14.36% to ¥29,992,667.09 from ¥26,225,857.82 year-on-year[10] - The net profit after deducting non-recurring gains and losses rose by 25.77% to ¥29,965,266.34 compared to ¥23,824,607.82 in the previous year[10] - Basic and diluted earnings per share were both ¥0.0404, a decline of 1.46% from ¥0.0410 in the previous year due to an increase in the number of shares outstanding[10] - Total operating revenue for the current period is CNY 409,036,863.19, a decrease of 1.3% from CNY 416,230,884.39 in the previous period[21] - Net profit for the current period reached CNY 29,086,075.84, an increase of 11.6% compared to CNY 26,057,158.43 in the previous period[22] - Operating profit increased to CNY 38,345,193.85, compared to CNY 34,701,575.17 in the previous period, reflecting a growth of 15.1%[22] - Total comprehensive income attributable to the parent company was CNY 29,989,909.88, compared to CNY 26,236,853.28 in the previous period, indicating an increase of 10.6%[22] Cash Flow and Assets - Cash flow from operating activities decreased by 32.86% to ¥68,679,664.08, down from ¥102,289,209.00 in the same period last year[10] - The company's cash and cash equivalents decreased to CNY 1,138,969,420.06 from CNY 1,240,041,262.14, a decline of about 8.2%[18] - The company reported a decrease in cash and cash equivalents at the end of the period to CNY 1,124,401,835.39 from CNY 519,518,553.40 in the previous period[26] - The total assets increased to CNY 3,546,266,054.50 from CNY 3,536,733,888.57, a growth of approximately 0.3%[19] - Total liabilities decreased to CNY 1,036,423,148.83 from CNY 1,058,411,535.22, a reduction of about 2.1%[19] - The company's net loss decreased to CNY -1,368,078,948.71 from CNY -1,398,071,615.80, indicating an improvement in financial performance[20] - Long-term borrowings increased to CNY 180,500,000.00 from CNY 152,601,666.67, reflecting a growth of approximately 18.3%[19] - The total equity increased to CNY 2,509,842,905.67 from CNY 2,478,322,353.35, a rise of about 1.3%[20] Shareholder Information - The company has a total of 17,573 common shareholders as of the end of the reporting period[12] - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of the shares, totaling 371,782,549 shares[12] - The company reported a total of 263,884,885 shares held by Qingdao Yinkang Medical Investment Co., Ltd., representing a significant portion of the unrestricted circulating shares[13] - The top ten unrestricted shareholders collectively hold a substantial number of shares, with the largest individual shareholder holding 1.47%[13] - As of March 31, 2025, the company has repurchased 6,156,752 shares, accounting for 0.82% of the total share capital[13] - The company has not reported any changes in the participation of major shareholders in margin trading activities[14] - There are no significant changes in the status of preferred shareholders or restricted shares[14] Acquisition and Investments - The company acquired 51% equity in Changsha Kexin Tumor Hospital for a total amount of RMB 357 million[14] - The acquisition aims to strengthen the company's presence in the oncology service sector and enhance its operational capabilities[15] - The funding for the acquisition will come from the company's own funds and self-raised funds[15] - After the transaction, Changsha Kexin will become a subsidiary and will be included in the company's consolidated financial statements[15] - The transaction was approved by the company's board and supervisory board, and does not require shareholder approval[15] Operating Costs and Revenue - Total operating costs decreased to CNY 365,010,030.67 from CNY 382,865,011.79, reflecting a reduction of approximately 4.7%[21] - Total revenue from operating activities was CNY 401,154,630.61, down 4.2% from CNY 418,030,793.48 in the previous period[25] - Cash flow from investing activities resulted in a net outflow of CNY 170,839,764.41, worsening from a net outflow of CNY 73,896,713.14 in the previous period[26] - The company incurred credit impairment losses of CNY -6,803,765.69, compared to CNY -3,026,574.95 in the previous period, indicating a significant increase in losses[22]

北京市金杜（青岛）律师事务所 关于盈康生命科技股份有限公司 2024 年年度股东大会之 法律意见书 致：盈康生命科技股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受盈康生命科技股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国 境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政 区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章、 规范性文件和现行有效的《盈康生命科技股份有限公司章程》（以下简称《公司 章程》）的有关规定，指派律师出席了公司于 2025 年 4 月 18 日召开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关事项出具本 法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 29 日刊登于巨潮资讯网及深圳证券交易所 ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-020 盈康生命科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过决议的情况。 一、会议召开和出席的情况 （一）会议召开情况 1、盈康生命科技股份有限公司（以下简称"公司"）2024 年年度股东大会通知 已于 2025 年 3 月 29 日以公告的形式向全体股东发出，具体内容详见公司刊登于巨 潮资讯网（www.cninfo.com.cn）的相关公告。 2、召开时间：现场会议召开时间为 2025 年 4 月 18 日（星期五）下午 14:30。 （1）通过深圳证券交易所交易系统投票 2025 年 4 月 18 日 9:15-9:25，9:30-11:30 和 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票 2025 年 4 月 18 日 9:15-15:00。 3、会议召开地点：山东省青岛市崂山区海尔路一号盈康一生大厦董事会议室。 4 ...

Group 1 - The core point of the article is that Yingkang Life plans to acquire a 51% stake in Changsha Kexin Oncology Hospital for 357 million yuan, which will allow it to gain control and consolidate the hospital's financials [2] - Changsha Kexin, established in 2015, is a tertiary oncology specialty hospital with 420 beds and reported revenue of 273 million yuan and net profit of 33.43 million yuan for the first three quarters of 2024 [2] - The hospital has committed to achieving net profits of no less than 57 million yuan, 58 million yuan, and 60 million yuan for the years 2025 to 2027, totaling 175 million yuan, which represents a significant increase of 73%-82% compared to historical performance [2] Group 2 - The acquisition is part of Yingkang Life's "1+n" strategy, which aims to establish a regional center hospital that supports multiple satellite hospitals [2] - Currently, Yingkang Life operates three owned hospitals and seven managed institutions, with projected medical service revenue of 1.192 billion yuan in 2024, where oncology revenue is expected to account for 31.9% [3] - Following the acquisition, Yingkang Life's total assets are reported at 3.537 billion yuan, with a debt ratio of 29.93%, indicating that total liabilities may increase post-acquisition [3]

Core Viewpoint - Yingkang Life announced the acquisition of 51% equity in Changsha Kexin Oncology Hospital for 357 million yuan, with an overall valuation of approximately 700 million yuan, resulting in a premium rate of 1429.99%, significantly exceeding the average merger premium in the healthcare industry [1][2] Group 1: Acquisition Details - The acquisition price of 357 million yuan corresponds to Changsha Kexin's net assets of 46.14 million yuan as of September 2024, indicating a high premium rate [1] - The acquisition will create approximately 280 million yuan in goodwill, accounting for 78% of the purchase price [2] Group 2: Financial Performance and Risks - Changsha Kexin has committed to net profits of 57 million, 58 million, and 60 million yuan for the years 2025 to 2027, respectively, but has only achieved a net profit of 33.42 million yuan in the first three quarters of 2024, indicating challenges in meeting these targets [2] - The realization of these profit commitments is dependent on uncontrollable factors such as local medical insurance policies and competition from public hospitals, which adds uncertainty to the performance outlook [2] Group 3: Historical Context and Concerns - Yingkang Life has previously faced issues with high premium acquisitions, such as the 2015 acquisition of Maxip, which resulted in 947 million yuan in goodwill and 804 million yuan in impairments by 2021 [3] - High premium acquisitions lead to increased goodwill on the balance sheet, which is essentially a prepayment for the future profitability of the acquired entity; if performance does not meet expectations, goodwill impairment will directly impact the company's profits [3] Group 4: Strategic and Operational Challenges - The strategic synergy of the acquisition is questionable, as Yingkang Life's core competencies lie in medical device R&D and oncology treatment technology, while Changsha Kexin operates as a regional hospital reliant on localized medical services [4] - The acquisition may dilute core business resources, as the high cash outflow could affect the development of key projects like high-end imaging equipment and AI diagnostic algorithms, leading to a diversion of management focus [4] - The regional oncology market is highly competitive, with public hospitals attracting patients away from private facilities, making it difficult for Changsha Kexin to maintain its market position [5]

Financial Performance - In 2024, Yingkang Life achieved revenue of CNY 1.559 billion, a year-on-year increase of 6.01% [9] - The medical services segment generated revenue of CNY 1.192 billion, up 3.76% year-on-year, while the medical device segment saw revenue of CNY 367 million, a growth of 14.05% [9] - The net profit attributable to shareholders reached CNY 115 million, reflecting a year-on-year growth of 14.92% [9] Cost Management - The company optimized its cost structure, with management expenses decreasing by 0.1 percentage points, sales expenses down by 0.6 percentage points, and financial expenses reduced by 0.1 percentage points [2][3] - R&D expenses amounted to CNY 54.52 million, accounting for 14.86% of medical device revenue, with a commitment to maintain reasonable levels of R&D investment [3] Strategic Initiatives - Yingkang Life is actively embracing AI technology to enhance operational efficiency and service quality, with a focus on a "three-full" concept: full participation, full coverage, and full process [7] - The company is transitioning from a traditional medical group to a health management technology company, leveraging AI to improve service efficiency and patient experience [8] Acquisition of Changsha Kexin Hospital - The acquisition of Changsha Kexin Hospital, a tertiary cancer specialty hospital, is expected to enhance Yingkang Life's business scale and profitability [11] - The hospital reported an audited revenue of CNY 273 million and a net profit of CNY 33.43 million for the first nine months of 2024, with performance commitments for the next three years [6] Market Outlook - The aging population in China is driving the growth of the silver economy, with increasing demand for healthcare services [14] - The private cancer hospital market is projected to reach CNY 106.7 billion by 2025, with the overall cancer medical service market expected to grow to CNY 700.3 billion [14] - The medical device industry is anticipated to surpass CNY 1.2 trillion in market size in 2024, supported by government initiatives and technological advancements [14]

星标 ★ IPO日报 精彩文章第一时间推送 背靠海尔集团公司（下称"海尔集团"），上市公司盈康生命科技股份有限公司（下称"盈康生命"，300143.SZ）即将迎来第四家自有医院。 近期，盈康生命发布公告，拟以3.57亿元现金收购长沙珂信肿瘤医院有限公司（下称"长沙珂信"）51%股权。在交易完成后，长沙珂信将成为盈康生命下 属控股子公司，纳入公司合并报表范围。 制图：佘诗婕 扩张医疗版图 近年来，海尔集团开始积极布局医疗健康领域。 据悉，苏州广慈肿瘤医院是一所二级甲等肿瘤医院。 除了上述3家医院，盈康生命旗下还有上海永慈康复医院等7家托管机构。 此次"拿下"长沙珂信这家三级肿瘤医院，也可以说是符合盈康生命战略的重要落子。盈康生命早年提出"1+n"战略（即1家区域中心医院带动多家卫星医 院），通过并购与托管加速区域医疗中心布局。 对于这次并购，盈康生命表示，并购标的肿瘤医疗服务收入占比高，将有力强化公司在肿瘤特色医疗领 域的战略布局。 增值率1429.99% 据了解，此前盈康生命就已与湖南珂信健康产业集团有限公司（下称"珂信集团"）、长沙珂信签署相关协议。根据协议，珂信集团向盈康生命承诺，长沙 珂信2025年度、 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 11.97 RMB [6][7]. Core Views - The company achieved a revenue of 1.559 billion RMB in 2024, representing a year-on-year growth of 6.01%, and a net profit of 115 million RMB, up 14.92% year-on-year, slightly below the consensus forecast of 120 million RMB [1][5]. - The hospital business is expanding steadily, driven by the strengths of Sichuan Friendship Hospital in oncology and the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million RMB, which will enhance the company's oncology business layout [1][2]. - The medical device segment is focusing on high-end and international strategies, with a revenue of 367 million RMB in 2024, reflecting a 14% year-on-year increase [4]. Summary by Sections Hospital Business - The hospital business generated 1.19 billion RMB in 2024, growing by 3.76% year-on-year, primarily due to stable revenue growth from Sichuan Friendship Hospital's oncology services [2]. - Sichuan Friendship Hospital achieved a revenue of 579 million RMB in 2024, up 10% year-on-year, with expectations for continued growth in 2025 [2]. - The acquisition of Changsha Kexin Tumor Hospital is expected to boost revenue, with the hospital generating 273 million RMB in revenue and a net profit of 33.43 million RMB in the first nine months of 2024 [2]. Medical Devices - The medical device segment's revenue reached 367 million RMB in 2024, driven by high-end product upgrades and breakthroughs in overseas markets [4]. - The company anticipates stable growth in this segment for 2025, supported by the recovery of Gamma Knife orders and the performance of Saint Nuo and Shenzhen Unimedic [4]. Profit Forecast and Valuation - The company forecasts earnings per share (EPS) of 0.19 RMB, 0.23 RMB, and 0.26 RMB for 2025, 2026, and 2027 respectively, with a target price set at 11.97 RMB based on a 63x price-to-earnings (PE) ratio for 2025 [5][6]. - The projected revenue for 2025 is 1.933 billion RMB, reflecting a year-on-year growth of 23.95% [5].